Literature DB >> 19356876

Development and validation of a reverse phase liquid chromatography method for the quantification of rasagiline mesylate in biodegradable PLGA microspheres.

Marcos Fernández1, Emilia Barcia, Sofía Negro.   

Abstract

In the present study, a reverse phase high performance liquid chromatographic method was developed and validated for the determination of rasagiline mesylate in biodegradable microspheres. Chromatographic separation was carried out on a RP-18 column using a mobile phase consisting of acetonitrile:water (5:95, v/v) adjusted at pH 3.1. Flow rate was 1.0 ml min(-1) and UV detection at 290 nm. Acyclovir was used as the internal standard. The calibration curve was linear over the range 0.5-20.0 microg ml(-1). R.S.D. for precision was <1.8%. Accuracy ranged between 99.01% and 102.55% with a R.S.D. lower than 1.3%. LOD and LOQ were 0.07 microg ml(-1) and 0.23 microg ml(-1), respectively. The method was simple, rapid, and easy to apply, making it very suitable for routine analysis of rasagiline mesylate in biodegradable PLGA microspheres. It could be also used with reliability for the determination of the drug in other pharmaceutical dosage forms.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19356876     DOI: 10.1016/j.jpba.2009.02.031

Source DB:  PubMed          Journal:  J Pharm Biomed Anal        ISSN: 0731-7085            Impact factor:   3.935


  3 in total

1.  Bio-analytical method development and validation of Rasagiline by high performance liquid chromatography tandem mass spectrometry detection and its application to pharmacokinetic study.

Authors:  Ravi Kumar Konda; Babu Rao Chandu; B R Challa; Chandrasekhar B Kothapalli
Journal:  J Pharm Anal       Date:  2012-05-11

2.  Reversed-Phase UHPLC Enantiomeric Separation of Rasagiline Salts Using a Chiralpak® AGP Column.

Authors:  Nagarajan Balaji; Sayeeda Sultana
Journal:  Sci Pharm       Date:  2017-07-19

3.  Preparation and evaluation of injectable Rasagiline mesylate dual-controlled drug delivery system for the treatment of Parkinson's disease.

Authors:  Ying Jiang; Xuemei Zhang; Hongjie Mu; Hongchen Hua; Dongyu Duan; Xiuju Yan; Yiyun Wang; Qingqing Meng; Xiaoyan Lu; Aiping Wang; Wanhui Liu; Youxin Li; Kaoxiang Sun
Journal:  Drug Deliv       Date:  2018-11       Impact factor: 6.419

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.